Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB518 in Advanced Solid Tumors
NCT06428331Phase 1Recruiting
- Sponsor
- Kelun-Biotech
- Start
- Jul 2024
- Primary completion
- Jun 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SKB518 in solid tumor, sponsored by Kelun-Biotech. Primary endpoints: Dose-limiting toxicity at 21 days and Maximum Tolerated Dose at 21 days. Started Jul 2024; status: recruiting.
02
Drugs
SKB518
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06428331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06428331.